Ribociclib For Hr+ Advanced Breast Cancer

Ribociclib for HR+ Advanced Breast Cancer

MONALEESA-2: improved OS seen in HR+ advanced breast cancer treated with ribociclib + letrozole

RIGHT Choice: ribociclib + ET vs combo chemo in aggressive HR+/HER2− advanced breast cancer

Study of Ribociclib and PDR001 in HR+ Metastatic Breast Cancer

Dana-Farber Cancer Institute

MONALEESA-3 OS results: fulvestrant/ribociclib in postmenopausal HR+/HER2- advanced breast cancer

MONALEESA-3: Ribociclib Plus Fulvestrant in HR+ mBC

Early RIBECCA results: ribociclib with letrozole for metastatic breast cancer

Frontline endocrine therapies and ribociclib in early stage HR+ HER2- breast cancer

Safety and efficacy of ribociclib and letrozole in advanced breast cancer – the MONALEESA-2 trial

Maintenance w/ ET + ribociclib after 1L chemotherapy in HR+/HER2- metastatic breast cancer

NATALEE and monarchE: ribociclib and abemaciclib in HR+/HER2- breast cancer

RIBECCA: ribociclib, a CDK4/6 inhibitor in ER+ breast cancer

Dr. Kelly on the FDA Approval of Ribociclib in HR+ Breast Cancer

ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-Wynne

European Society for Medical Oncology (ESMO)

Encouraging Findings With Ribociclib in HR+ Breast Cancer

Targeted Oncology

HR–positive advanced breast cancer: Ribociclib improved PFS for pre and perimenopausal women

Ribociclib in adjuvant HR+ breast cancer

OncBrothers: Practice-Changing Cancer Discussions

Current state of CDK4/6 inhibitors in metastatic HER2-negative breast cancer

MONALEESA-2: ribociclib + letrozole in pts with de novo metastatic disease and late recurrence

NEW TREATMENT FOR ADVANCED BREAST CANCER: RIBOCICLIB